News
NURPF
14.00
NaN%
--
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF) and Ramsay Health Care (OtherRMSYF)
TipRanks · 2d ago
Neuren Files Final Director’s Interest Notice for Patrick Davies
TipRanks · 11/12 11:12
Neuren Appoints Zita Peach as Board Chair
TipRanks · 11/12 11:04
Macquarie Sticks to Their Buy Rating for Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 11/06 05:05
*Neuren Pharmaceuticals Price Target Raised 6% to A$26.00/Share by Macquarie
Dow Jones · 11/06 01:28
Ord Minnett Sticks to Its Buy Rating for Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 11/06 00:46
Analysts’ Top Healthcare Picks: Neuren Pharmaceuticals Limited (NURPF), Sight Sciences (SGHT)
TipRanks · 11/06 00:10
*Neuren Pharmaceuticals Price Target Raised 4.8% to A$34.88/Share by Petra Capital
Dow Jones · 11/05 23:23
*Neuren Pharmaceuticals Price Target Raised 3.9% to A$26.50/Share by Bell Potter
Dow Jones · 11/05 22:13
*Neuren Pharmaceuticals Price Target Raised 2.8% to A$29.70/Share by Jefferies
Dow Jones · 11/05 21:24
*Neuren Pharmaceuticals Price Target Raised 3.3% to A$27.80/Share by Barrenjoey
Dow Jones · 11/05 21:17
DAYBUE Growth Lifts Neuren Royalties and Adds German Milestone
TipRanks · 11/04 23:56
FDA Grants Orphan Drug Designation to Neuren’s NNZ-2591 for HIE
TipRanks · 11/01 23:53
Neuren’s Rett Drug Trofinetide Gains U.S. Patent Extension to 2041
TipRanks · 09/29 00:48
Neuren updates currency handling for June 2026 dividend
TipRanks · 09/18 06:28
Neuren Pharmaceuticals Limited (NURPF) Receives a Buy from Ord Minnett
TipRanks · 09/04 00:35
Neuren Highlights Neurodevelopment Focus and Development Risks
TipRanks · 09/01 23:28
Canaccord Genuity Remains a Buy on Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 08/30 23:37
Neuren Pharmaceuticals Earnings Call Signals Cash-Fueled Growth
TipRanks · 08/30 00:18
Jefferies Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 08/27 12:17
More
Webull provides a variety of real-time NURPF stock news. You can receive the latest news about Neuren Pharma through multiple platforms. This information may help you make smarter investment decisions.
About NURPF
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is developing new drug therapies to treat multiple serious neurological disorders that are caused by genetic abnormalities or brain injury and have no or limited approved treatment options. Its product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. Its other product, NNZ-2591, is an investigational medicine in Phase III clinical trial for Phelan-McDermid syndrome. Its NNZ-2591 other programs include Pitt Hopkins syndrome, Angelman syndrome, Prader-Willi Syndrome and SYNGAP1-related disorder. The United States Food and Drug Administration (FDA) and European Medicines Agency have both granted Orphan drug designation for trofinetide in Rett syndrome and Fragile X syndrome and for NNZ-2591. The Company has granted a worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.